Aspirin enhances the sensitivity of colon cancer cells to cisplatin by abrogating the binding of NF-κB to the COX-2 promoter
Wei Jiang, Yue Yan, Manyu Chen, Guangyu Luo, Jiaojiao Hao, Jinjin Pan, Sheng Hu, Ping Guo, Wenyang Li, Ruozu Wang, Yan Zuo, Yao Sun, Silei Sui, Wendan Yu, Zhe Pan, Kun Zou, Zongheng Zheng, Wuguo Deng, Xiaojun Wu, Wei Guo
Abstract
study also verified the enhanced anti-tumor activity of such combined therapy in colon cancer by targeting the NF-κB/COX-2 signaling. Our results provided new insights into understanding the molecular mechanisms of aspirin in sensitizing cisplatin-mediated chemotherapeutic effect in colon cancer and indicated a great potential of this combined therapy for cancer treatment.
Topics & Concepts
CisplatinAspirinCancer researchProtein kinase BColorectal cancerNF-κBMAPK/ERK pathwayPharmacologyIn vivoCancerSignal transductionCell growthApoptosisCancer cellMedicineCarcinogenesisChemistryBiologyInternal medicineChemotherapyBiochemistryBiotechnologyInflammatory mediators and NSAID effectsEstrogen and related hormone effectsChemotherapy-induced organ toxicity mitigation